About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Functional Lung Imaging With DECT and 4DCT | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04702607

Functional Lung Imaging With DECT and 4DCT

The basic premise of this pilot study is to enroll 40 patients over 3 years who have Stage II, III, or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradia...

Lead sponsor: Abramson Cancer Center at Penn Medicine•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Abramson Cancer Center at Penn Medicine

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients have histologic diagnosis of non-small cell lung cancer
•Patients have AJCC stage II, III or IV disease were the plan is to receive definitive concurrent chemoradiation to 60 Gy or higher
•Age \> 18 years of age
•Patients are able to provide informed consent
•No additional lung radiation is planned until after the 2nd CT on this study (i.e. patient does not have a solitary pulmonary nodule or second primary that the plan is to undergo SBRT)
•Patient must have adequate kidney function to receive IV contrast (following institutional policy supplied by radiology). The cutoff level for serum creatinine is 1.6 mg/dL
•Negative urine pregnancy test before every CT scan

Exclusion Criteria

•Allergy to IV iodine contrast
•Severe claustrophobia
•Further thoracic radiation therapy is planned.

Related studies

RECRUITINGPhase 3

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510 · Non Small Cell Lung Cancer

RECRUITINGPhase 4

Dabrafenib and/or Trametinib Rollover Study

NCT03340506 · Melanoma, Non Small Cell Lung Cancer, and more

RECRUITINGPhase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138 · Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, and more

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114 · Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer, and more

RECRUITINGPhase 1/2

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132 · Advanced Solid Tumor, Non Small Cell Lung Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 5, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment40

Start dateJan 2021

Last updatedNov 5, 2024

Condition

Non Small Cell Lung Cancer

Locations shown

Abamson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 5, 2024Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions